A股異動 | 科華生物(002022.SZ)連續2日跌停 被申請仲裁 涉及金額105億
格隆匯7月15日丨科華生物(002022.SZ)跌停,為連續第二日封跌停板。報14.14元創近一年半新低,總市值為72.78億元。科華生物13日公吿,彭年才等就與公司簽訂的《關於西安天隆科技有限公司和蘇州天隆生物科技有限公司之投資協議書》所引起的爭議向上海國際經濟貿易仲裁委員會提出仲裁申請並獲受理,要求公司支付剩餘投資價款105億元。涉及金額遠超目前公司總市值。公司同時公佈上半年淨利同比預增108%-154%。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.